With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch

19th October 2017 Uncategorised 0

Novo Nordisk is one step closer to approval for semaglutide, the weekly diabetes drug it sees as a best-in-class follow-up to its blockbuster daily injection, Victoza. Next up? FDA label discussions, payer talks and prep for a market tussle with Eli Lilly’s Trulicity.

More: With FDA panel backing, Novo Nordisk prepares for semaglutide's potential launch
Source: fierce